The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tetrahydrouridine/decitabine/5-azacytidine for non-cytotoxic epigenetic-immunotherapy of NSCLC in vivo.
 
Kai Kang
No Relationships to Disclose
 
Arjun Khunger
No Relationships to Disclose
 
David S. Schrump
No Relationships to Disclose
 
Mark P. Rubinstein
No Relationships to Disclose
 
John M. Wrangle
No Relationships to Disclose
 
Yogen Saunthararajah
Stock and Other Ownership Interests - Acceleron Pharma; Celgene
Consulting or Advisory Role - EpiDestiny
Patents, Royalties, Other Intellectual Property - -Patents around tetrahydrouridine and decitabine licensed to EpiDestiny. - Unpaid consultancy for EpiDestiny.
 
Vamsidhar Velcheti
Honoraria - Bristol-Myers Squibb; Foundation Medicine; Genentech/Roche; Merck; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Clovis Oncology; Foundation Medicine; Genentech; Genoptix; Merck; Takeda
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); Trovagene (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai; Foundation Medicine; Merck